<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00878527</url>
  </required_header>
  <id_info>
    <org_study_id>CircuLite CRP-001</org_study_id>
    <nct_id>NCT00878527</nct_id>
  </id_info>
  <brief_title>Safety and Performance Evaluation of CircuLite Synergy</brief_title>
  <official_title>Safety and Performance Evaluation of the CircuLite Synergy Pocket Circulatory Assist Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to demonstrate the safety and functionality of the CircuLite
      Synergy Pocket Circulatory Assist Device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CircuLite Synergy Pocket Circulatory Assist Device is an implantable miniature,
      mixed-flow blood pump designed o provide partial left ventricular support in patients with
      advanced heart failure. Treatment for this patient population currently include lifestyle
      changes, medicines, transcatheter interventions and surgery, including implantation of
      mechanical ventricular assist devices (VADs); most of the currently available VADs require
      highly invasive, high-risk surgical procedures to implant due to large device size, and are
      therefore generally limited to use in patients with terminal heart failure. The Synergy pump
      is intended for treatment of patients with New York Heart Association (NYHA) Class III and IV
      heart failure; it is expected that the pump will provide these patients with 2-3 L/min of
      additional blood flow, giving adequate cardiac support to increase exercise tolerance and
      improve patients' quality of life. The pump's small size will allow it to be implanted in a
      less surgically invasive procedure than used with previous VADs, which should result in a
      reduction of perioperative morbidity. The device wil be implanted in a left atrial to
      subclavian artery bypass with the pump being located in the infraclavicular fossa like a
      pacemaker.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety - Adverse Events</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluation of the incidences of device failure or malfunction, adverse events associated with device use, surgical complications with device implant, and demonstration that the device provides adequate circulatory support in advanced HF patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in hemodynamics</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluation of changes across time in hemodynamics, exercise tolerance, neurohormones, quality of life, functional capacity and ventricular function to determine the incidence of worsening HF in patients while supported by the CircuLite Synergy Device.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Treatment with the pump</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with the CircuLite Synergy Pocket Circulatory Assist Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CircuLite Synergy Pocket Circulatory Assist Device</intervention_name>
    <description>Goal of successful implantation and follow-up for at least three months</description>
    <arm_group_label>Treatment with the pump</arm_group_label>
    <other_name>CircuLite</other_name>
    <other_name>CircuLite Synergy</other_name>
    <other_name>CircuLite Micro pump</other_name>
    <other_name>CircuLite Synergy Partial Circulatory Assist Device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Maximum tolerable medical therapy including ACE inhibitors and Beta Blockers

          -  NYHA Class III or IV despite maximal tolerable medical therapy

          -  Ambulatory (inpatient or outpatient)

          -  Patients on the heart transplant list (or, not currently listed but otherwise suitable
             for heart transplant)

          -  Life expectancy of at least 6 months without full VAD support

        Exclusion Criteria:

          -  Age &gt;75 years

          -  Exercise tolerance limited by factors other than heart failure

          -  Presence of intra-atrial thrombus

          -  Clinically significant right heart failure

          -  Serum creatinine &gt;/= 2.5 mg/dl or any dialysis in previous 3 months

          -  Evidence of intrinsic hepatic disease

          -  Previous episode of resuscitated sudden death without subsequent treatment with AICD

          -  Subclavian artery stenosis

          -  Low platelet count, INR that cannot be corrected prior to implant or contraindication
             to anticoagulation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>German Heart Centre Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Center Cologne University Hospital</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical School Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Centre University Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Muenster</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humanitas Clinical and Research Center</name>
      <address>
        <city>Milan</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Cardiovascular Diseases Bratislava</name>
      <address>
        <city>Bratislava</city>
        <zip>83348</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harefield Hospital</name>
      <address>
        <city>Harefield</city>
        <zip>UB9 6JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Slovakia</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Morley D, Litwak K, Ferber P, Spence P, Dowling R, Meyns B, Griffith B, Burkhoff D. Hemodynamic effects of partial ventricular support in chronic heart failure: results of simulation validated with in vivo data. J Thorac Cardiovasc Surg. 2007 Jan;133(1):21-8.</citation>
    <PMID>17198776</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2009</study_first_submitted>
  <study_first_submitted_qc>April 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2009</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Partial Circulatory Assist</keyword>
  <keyword>NYHA Class IIIb</keyword>
  <keyword>NYHA Class IV</keyword>
  <keyword>Ventricular Assist Device</keyword>
  <keyword>VAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

